Carfilzomib prolonged PFS in relapsed multiple myeloma

December 7, 2014 2:00 AM

1 0

SAN FRANCISCO — The addition of carfilzomib to lenalidomide plus dexamethasone significantly extended PFS in patients with relapsed multiple myeloma who received one to three prior therapies, according to phase 3 study results presented at the ASH Annual Meeting and Exposition.

“Patients with multiple myeloma in the trial who received Kyprolis [carfilzomib] as part of their treatment stayed in remission for more than 2 years and were in complete remission three times more frequently than those patients receiving the standard of care,” A. Keith Stewart, MB.ChB., dean for re...

Read more

To category page